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Abstract
Alopecia areata is an organ-specific autoimmune disease targeting hair follicles. It causes 
nonscarring hair loss. The prevalence rate of the disease is approximately 1 in 1000 peo-
ple worldwide. The condition is most commonly seen as circular areas of hair loss, but it 
may sometimes be as extensive as to involve the whole scalp or whole body. The complex 
pathophysiology of alopecia areata involves an autoimmune basis. Association of alope-
cia areata with other autoimmune diseases, such as thyroiditis and vitiligo, and the good 
response of patients to immunosuppressive treatment support an autoimmune etiology. 
Although some poor prognostic signs are defined, the course of the disease is unpredict-
able and the response to treatment can be variable. To date, there are neither preventive 
nor curative measures to deal with the condition. First-line therapy for patchy disease is 
topical and intralesional steroids, whereas extensive disease is conventionally managed 
with immunotherapy. New treatment agents, such as excimer laser, low-dose recom-
binant interleukin 2, Janus kinase inhibitors, and simvastatin/ezetimibe, are promising.
Keywords: alopecia areata, pathogenesis, autoimmunity, squaric acid dibutylester 
(SADBE), diphenylcyclopropenone (DPCP)
1. Introduction
Alopecia areata is an organ-specific autoimmune disease targeting hair follicles. It causes non-
scarring hair loss. The condition is most commonly seen as circular areas of hair loss, but may 
sometimes be as extensive as to involve the whole scalp or whole body [1]. Although some 
poor prognostic signs are defined, the course of the disease is unpredictable and the response 
to treatment can be variable [2]. To date, there are neither preventive nor curative measures 
to deal with the condition [3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provi ed the origi al work is properly cited.
2. Epidemiology
Alopecia areata is the most prevalent autoimmune disorder and the second most frequent 
disease causing hair loss after androgenetic alopecia [3]. The prevalence rate of the disease is 
approximately 1 in 1000 people worldwide; in the United States, the lifetime risk is estimated 
to be 1.7% [2, 4]. Alopecia areata is mainly a disease of young adults; as many as 60% of 
patients are under the age of 20 at first presentation. Pediatric cases constitute approximately 
20% of alopecia areata patients [2]. However, patients of any age can be affected. There is no 
gender predilection [4]. Reported cases in elderly were of milder severity and had a better 
treatment response [5].
3. Pathogenesis
Alopecia areata is an organ-specific T cell mediated autoimmune disease targeting hair fol-
licles. Peribulbar lymphocytic infiltration impairing the normal hair cycle is considered to be 
the main pathophysiologic mechanism responsible for the disease process. Normal hair cycle 
is disrupted in alopecia areata; dystrophic changes of anagen follicles along with rapid pro-
gression of hair follicles from anagen to catagen and telogen phases are observed. In alopecia 
areata, perifollicular inflammatory infiltrate spares the bulge region of the follicle where fol-
licular epithelial stem cells reside. Thus, in contrast to cicatricial alopecias, the inflammation 
does not interfere with the hair follicle integrity [6].
The complex pathophysiology of alopecia areata involves an autoimmune basis. Association 
of alopecia areata with other autoimmune diseases such as thyroiditis and vitiligo is reported. 
Presence of lymphocytes around hair follicles and the good response of patients to immuno-
suppressive treatment also support autoimmune etiology [2].
Etiopathogenetic theories are based upon the loss of immune-privileged status of hair fol-
licles leading to an immune response against follicular antigens. In fact, normal proximal 
epithelium of anagen hair follicles have a very low expression of MHC class I antigens and 
no MHC class II antigen expression, along with a potent expression of immunosuppressive 
cytokines, such as TGF-β1 and α-melanocyte–stimulating hormone (α-MSH) [6]. According to 
the recent evidence, mechanism leading to hair loss involves the following steps: firstly, hair 
follicles must enter an anagen phase without the immune privilege described above, making 
those vulnerable to immune reactions. Subsequently, perifollicular CD8+ T cell infiltration of 
the anagen hair bulb epithelium ensues, along with a significant increase in interferon-gamma 
(IFN-γ) and various other cytokines. This milieu further damages the immune-privileged 
status of hair follicles, autoreactive CD8+ T lymphocytes, and IFN-γ and causes hair follicle 
dystrophy and premature catagen induction, leading to clinical hair loss [7]. Patients with 
alopecia areata have also been found to have an increased frequency of hair follicle-specific 
autoantibodies [2].
Genetic basis is implicated in disease pathogenesis. Many patients report a family history of 
alopecia areata with a frequency ranging from 10% to 42% of cases [8]. Studies show a higher 
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concordance rate among monozygotic twins compared to dizygotic twins also supporting the 
role of genetics [9]. HLA-DRB1*1104 and DQB1*03 loci that have a role in regulating immu-
nity is associated with susceptibility to alopecia areata [2].
Genome-wide association studies can recognize specific individual genes, which may rep-
resent an increased susceptibility to alopecia areata. Petukhova et al. surveyed the entire 
genome and identified 139 single nucleotide polymorphisms associated with alopecia areata. 
The study showed that genomic regions containing the CTLA4, IL2/IL21, IL-2RA and Eos 
genes regulating proliferation of inflammatory cells to be susceptibility loci for alopecia 
areata. Ligands for the NKG2D receptor were also found to be implicated in disease patho-
genesis [10]. Mouse models for alopecia areata gave valuable information regarding the role 
of CD8+ NKG2D+ T lymphocytes in pathogenesis. Transfer of these cytotoxic cells from mice 
with alopecia areata induced alopecia areata in healthy mice; on the other hand, NKG2D+ T 
cell-depleted lymph node cells transferred from the diseased mice to the healthy mice did not 
cause any disease. Interferon produced by NKG2D+ T cell is thought to contribute to the loss 
of immune-privileged status of hair follicles [11].
4. Clinical features
Alopecia areata patches are mostly asymptomatic and are discovered incidentally. Rarely, 
patients may complain of burning or itching sensation preceding hair loss. Typically, hair 
loss presents as one or more well-demarcated round to oval skin-colored patches [1]. The 
affected skin has a normal appearance with visible follicular orifices. Rarely, a soft edematous 
infiltration can be felt upon palpation and a peachy or reddened coloration can be observed 
[12]. Any hair-bearing site may be affected [1]. The scalp is the most common site of involve-
ment, with or without the involvement of other body sites, such as the eyebrows, eyelashes, 
and beard [3].
According to the extent of involvement, alopecia areata can be classified into alopecia cir-
cumscripta presenting with limited hair loss, alopecia totalis involving the entire scalp, and 
alopecia universalis involving whole body (Figures 1 and 2).
A clinical classification regarding the pattern of hair loss is also frequently used. Patchy alope-
cia is the most common type seen in up to 75% of patients. Reticular type has a net-like pattern 
with multiple active and regressing patches (Figure 3). A band-like pattern involving occipital 
scalp is called ophiasis type of alopecia areata. The very rare ophiasis inversus, also called 
sisaipho type, presents with hair loss in the central scalp, resembling androgenetic alopecia 
[12]. Another unusual variant, perinevoid alopecia, is reported as presenting with alopecia 
patches around the nevi [13]. Diffuse alopecia areata presents with widespread thinning of 
the scalp hair. A recently defined variant, acute diffuse and total alopecia is characterized 
with rapid progression, female preponderance, and a favorable prognosis [14].
Initially, white hairs may be spared in patients with graying hair. As disease progresses, the 
white hair will also be lost. Initial hair regrowth, spontaneous or therapy-induced may be 
depigmented or hypopigmented, but the color usually returns with time [2].
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Nail changes are observed in up to 7–66% of patients [15]. The nail matrix may be affected, 
resulting in pitting of the nail plate, which is the most common nail involvement in alopecia 
areata [6]. Other nail features found in alopecia areata are trachyonychia, Beau's line, ony-
chorrhexis, onychomadesis, koilonychias, punctuate or transverse leukonychia, and red-spot-
ted lunula [16]. Nail disease may precede, follow, or coexist with active hair loss [2].
5. Associated diseases
Alopecia areata is associated with many diseases, including other autoimmune diseases, 
atopy, ophthalmologic findings and psychiatric comorbidities.
Among autoimmune disorders, the two main associations are with thyroid disease and vit-
iligo [17]. Incidence of thyroid disease varies from 8% to 28% in patients with alopecia areata, 
compared with only 2% of the normal population. Among thyroid disorders, hypothyroid-
ism is the most frequent association. [18] Prevalence of antithyroid antibodies is shown to 
be increased, but thyroid antibodies do not have any clinical correlation with disease sever-
ity [19]. Alopecia areata has also been shown to have a significant association with vitiligo; 
patients have a fourfold greater incidence of vitiligo compared with normal population. There 
are also reported associations of alopecia areata with pernicious anemia, lupus  erythematosus, 
 myasthenia gravis, rheumatoid arthritis, polymyalgia rheumatica, ulcerative colitis, and 
lichen planus [8]. A very strong disease association with the autosomal recessive disease auto-
immune polyglandular syndrome type 1 (APS-1, chronic hypoparathyroidism-mucocutane-
Figure 1. Circular area of nonscarring alopecia incidentally found in an adult patient.
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ous candidiasis-autoimmune adrenal insufficiency) was recently reported [20]. Patients with 
Down's syndrome or Turner's syndrome also have increased risk of alopecia areata [17].
Atopic disorders, namely allergic rhinitis, asthma, and atopic dermatitis have been linked 
to alopecia areata. They have been found to occur in more than 40% of patients with alo-
pecia areata, whereas their prevalence in the general population is estimated to be around 
20% [17].
Interestingly, there is a decreased incidence of type 1 diabetes in alopecia areata patients and 
an increased incidence in their relatives. It was proposed that alopecia areata may have a pro-
tective effect against type 1 diabetes in predisposed individuals [21].
Ocular alterations, such as asymptomatic punctate lens opacities, and fundus changes can 
occur in up to 50% of patients with alopecia areata [22].
There may be a high psychiatric morbidity in alopecia areata patients. Depression, increased 
level of anxiety, generalized anxiety disorder, social phobia, posttraumatic stress disorder, 
and suicidal thoughts are among the reported psychiatric disturbances [23].
Incidence of nuchal nevus flammeus was reported to be increased in alopecia areata patients, 
especially in those showing a more severe course of the disease [24].
Figure 2. A patient with alopecia universalis having total loss of scalp hair and eyebrows.
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6. Prognosis
The disease has an unpredictable course; spontaneous regrowth of hair is common as observed 
in about 80% of patients within one year [25]. However, patients usually present with several 
episodes of hair loss and hair regrowth during their lifetime [8]. Progression to alopecia totalis 
and universalis may occur in 5–10% of patients [3].
Extent of involvement (alopecia totalis/universalis)
Younger age of onset
Family history
Atopy
Ophiasis
Nail changes
Associated autoimmune disease
Table 1. Poor prognostic factors.
Figure 3. Reticular type alopecia areata with a net-like pattern.
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Some clinical factors that indicate a poor prognosis is defined (Table 1). The most important 
factor is the extent of the disease [1]. The chance of full recovery is less than 10% in alope-
cia totalis and universalis [12]. Acute diffuse and total alopecia variant constitutes an excep-
tion. As discussed earlier in this chapter, these patients have a favorable treatment response 
despite the substantial hair loss [15]. Other factors reported are young age at disease onset, a 
positive family history, atopy, ophiasis pattern of loss, nail changes, and associated autoim-
mune diseases [8, 15]. Positive family history is associated with the early age of onset. In fact, 
positive family history among first-degree relatives has been reported to be as high as 47% for 
patients with early onset, in contrast to 1.6% for all patients [6].
7. Diagnosis
Diagnosis of alopecia areata is made on clinical grounds. No routine laboratory investiga-
tions are needed. Routine thyroid screening is not indicated but screening may be performed 
in long-standing cases, females, patients with persistent patches, and patients with alopecia 
totalis and universalis [8].
Upon examination, exclamation mark hairs may be observed within or at the periphery of the 
lesions that are short hairs tapered towards their base [1]. Exclamation mark hairs occur only 
in acute forms of alopecia areata and are not seen in patients with long-standing areas of hair 
loss [15]. Pull test can be performed to assess disease activity; six hairs or more shed from the 
periphery of the lesion positively correlates with the disease activity [16].
Severity of the disease can be measured by SALT score, developed by the National Alopecia 
Areata Foundation working committee. The scalp is divided into 4 parts, the top constituting 
40% of total surface, the posterior 24%, right side and left side of scalp 18% each. Percentage 
of hair loss in each area is determined and is multiplied by the percentage of scalp covered in 
that area of the scalp, and summing the products of each area will give the SALT score [26].
Several studies have shown that dermoscopy may be a useful tool to help in the diagnosis of 
alopecia areata. Dermatoscopic findings reported in the literature include: yellow dots, black 
dots, short vellus hairs, black dots, tapering hairs, and broken hairs [27].
In ambiguous cases, a scalp biopsy is required. Histopathological examination of 4 mm punch 
biopsy containing subcutaneous fat is necessary to establish correct diagnosis. Biopsy should 
be taken from the periphery of the lesion as this is the site where the disease activity is found 
[28]. Horizontal sections will give a better representation of the histopathology especially in 
bulb infiltration than vertical sections [29].
8. Histopathology
Histopathology depends on the stage of the disease [30]. In the acute stage, there is a dense 
inflammatory infiltrate surrounding the terminal anagen hair bulb situated in the deep subcu-
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taneous tissue. Inflammatory infiltrate consists primarily of T lymphocytes and Langerhans 
cells, with occasional eosinophils, mast cells, and plasma cells [31, 32]. An early and typical 
feature is the presence of eosinophils in stellae and within hair bulbs [29]. Anagen hairs cycle 
through catagen then into telogen. A dense lymphocytic inflammation can cause breaking 
of the hair shaft with a trichorrhexis nodosa-like fracture. This is the exclamation point hair, 
which is in telogen phase and therefore shed [31, 32]. The horizontal section demonstrates 
a significant decrease in the anagen:telogen ratio. There is also a decrease in the number of 
terminal hairs with a slight increase in the number of vellus hairs [31].
In the subacute stage, the number of catagen hairs is markedly increased [30]. The number of 
telogen hairs also increases after a few weeks. The amount of terminal hairs decreases and the 
vellus hair increases [31, 32].
In the chronic stage, either no or a mild chronic peribulbar lymphocytic inflammation around 
the miniaturized hairs situated in the papillary dermis is observed [30, 31]. The terminal:vellus 
hair ratio decreases to 1.3:1 rather than 7:1, which is found in the normal population. Fibrosis 
is an uncommon finding. However, in approximately 10% of the patients with a long history 
of alopecia areata, fibrosis of the upper follicle can be detected [31].
Of note, diagnosis of alopecia areata does not depend on the presence of an inflammatory infil-
trate. Histopathological examination reveals increased numbers of telogen hairs in the acute 
and chronic stages, increased miniaturized hairs in chronic stage, and markedly increased 
catagen hairs in the subacute stage, helping in the diagnosis of alopecia areata [30].
9. Differential diagnosis
Many other diseases may cause hair loss in a patchy or diffuse pattern [33, 34] (Table 2).
In children, tinea capitis, which is the most common dermatophyte infection seen in child-
hood and trichotillomania should be considered in differential diagnosis of alopecia areata. 
Clinically, patches of tinea capitis show scaling and signs of inflammation sometimes accom-
panied by cervical lymphadenopathy. Direct microscopic examination with potassium 
hydroxide, fungal culture, and trichoscopy can also help in the diagnosis [35]. In trichotil-
lomania, diagnosis is straightforward when the patient or relatives accept the compulsive act 
of pulling. In dermatological examination, there are irregularly shaped patches and broken 
hairs of variable lengths. Residual hairs in patches of trichotillomania are anagen hairs firmly 
attached to the scalp; they are of normal texture and color, whereas residual hairs in alopecia 
areata are usually the exclamation mark hairs with their specific morphology, which are eas-
ily detached from the scalp. [33, 36] Rarely, alopecia areata and trichotillomania can coexist 
[37]. Histopathologically, there is an increase in catagen hairs, follicular hemorrhage, pigment 
casts, and trichomalacia, without the typical inflammatory infiltrate and miniaturization of 
hair follicles observed in alopecia areata [31, 36].
In adults, the differential diagnosis is usually between androgenetic alopecia and telogen 
effluvium. Patients with androgenetic alopecia usually demonstrate gradual loss of hair with 
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the typical distribution pattern. The pull test is usually negative in androgenetic alopecia [8]. 
In some cases, a scalp biopsy may be required to establish correct diagnosis. Many miniatur-
ized hairs are found in both androgenetic alopecia and alopecia areata, but higher telogen hair 
counts and a decreased anagen to telogen ratio favors diagnosis of alopecia areata. Although a 
perifollicular lymphohistiocytic infiltrate may be observed in androgenetic alopecia, it is usu-
ally confined to the upper follicle [31]. Telogen effluvium may be difficult to differentiate from 
diffuse alopecia areata. In alopecia areata, hair pull test show either telogen or dystrophic 
anagen hairs, while they are purely telogen in telogen effluvium [2]. Upon histopathologic 
examination of horizontal sections of scalp biopsies, chronic telogen effluvium shows follicu-
lar counts that are similar to that of normal controls [31].
Cicatricial alopecia is characterized by patchy hair loss with loss of follicular orifices. 
Erythema, scaling, and pustulation may be observed in contrast to smooth, normal skin of 
alopecia areata patches [15]. Other forms of alopecia, such as syphilis, loose anagen syn-
drome, congenital triangular alopecia, and early lupus erythematosus, should also be con-
sidered [31]. Congenital triangular alopecia is a developmental abnormality of hair follicles 
that usually presents after 2 years of age as a triangular or round patch of hair loss near the 
frontotemporal hair line. Histopathological examination reveals vellus hairs [34]. Side pins 
used to keep the hair in place, may cause pressure alopecia, which presents with a patch of 
hair loss mimicking patches of alopecia areata [38]. Traction alopecia must be differentiated 
from alopecia areata, especially of ophiasis pattern [39].
10. Management
Currently, there is no curative or preventive treatment for alopecia areata. The main goal of 
therapy is to suppress the disease activity [16].
Tinea capitis
Trichotillomania
Androgenetic alopecia
Telogen effluvium
Cicatricial alopecia
Secondary syphilis
Loose anagen syndrome
Congenital triangular alopecia
Lupus erythematosus
Pressure alopecia
Traction alopecia
Table 2. Differential diagnosis of alopecia areata.
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10.1. Intralesional corticosteroids
Intralesional corticosteroids have been used in treatment of alopecia areata, since 1958 [38]. 
Intralesional corticosteroids are considered as the first-line agents in limited alopecia areata. 
Injections are made every 4–6 weeks into the deep dermis using a 0.5-inch long 30-gauge 
needle. For lesions of the scalp, 0.1 mL of triamcinolone acetonide at concentration of 5 mg/
mL is injected at 1-cm intervals. Intralesional corticosteroid application is also effective for 
beard and eyebrow alopecia areata at a concentration of 2.5 mg/mL. Maximum dose of triam-
cinolone acetonide should be limited to 3 mL for scalp, 0.5 mL for each eyebrow and 1 mL for 
beard [40]. Hair regrowth is usually observed within 4 weeks and intralesional corticosteroids 
should be discontinued, if there is no improvement in 6 months [28]. In some patients, resis-
tance to steroid therapy can be explained by a decreased expression of thioredoxin reductase 
1, an enzyme that activates the glucocorticoid receptor in the outer root sheath [41]. The most 
common side effect observed is atrophy, which may be prevented by avoiding superficial 
injections, and reducing the concentration and volume of injections [42]. Other side effects 
include hypopigmentation, depigmentation, and telangiectasias [40].
10.2. Topical corticosteroids
Midpotent and potent topical corticosteroids in forms of lotions, creams, and ointments are 
widely used in spite of the fact that evidence of their effectiveness is limited [42, 43]. In a 
double-blind placebo-controlled study, rate of complete hair growth was not statistically sig-
nificant with 12 weeks use of 0.25% desoximetasone cream, twice daily, when compared with 
placebo [44]. A half-head comparison trial performed with 0.05% clobetasol propionate foam 
and vehicle found at least 50% regrowth of hair after 12 weeks of clobetasol treatment. Blood 
levels of cortisol and ACTH were not affected during the trial [45]. A recent study showed that 
twice daily treatment with clobetasol propionate 0.05% cream used in 2 cycles of 6 weeks on, 
6 weeks off regimen for a total of 24 weeks was more effective than hydrocortisone 1% cream 
used in the same regime. Compared with only 33.3% of the children in the hydrocortisone 
group, 85% of the children in the clobetasol group had at least 50% reduction in the surface 
area with hair loss at 24 weeks [46]. Folliculitis is a common side effect; skin atrophy and tel-
angiectasia can rarely be observed [47].
10.3. Topical immunotherapy
Topical immunotherapy is the most effective treatment option for patients with chronic severe 
alopecia areata, with greater than 50% scalp involvement [48].
Topical immunotherapy consists of applying a contact allergen to induce a low-grade chronic 
dermatitis. The mechanism of action is still unclear. Antigenic competition, induction of lym-
phocyte apoptosis, and diversion of the T cell response from the hair follicle to the epidermis 
are among the various suggested theories [49–60].
Dinitrochlorobenzene was the first topical sensitizer to be used in the treatment of extensive 
alopecia areata; however, it was abandoned because of its mutagenic effects [42, 51]. Squaric acid 
dibutylester (SADBE) and diphenylcyclopropenone (DPCP) are the two compounds still in use 
today. Although SADBE is an ideal immunogen that is not found in the natural environment and 
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is not known to cross-react with other chemicals, DPCP is preferred because it is cheaper and is 
more stable in acetone for storage [42, 51]. DPCP is a very light sensitive compound and should 
be stored in amber bottles to protect it from exposure to ultraviolet and fluorescent lights [51].
Topical immunotherapy begins at first visit by the sensitization of the patient with 2% DPCP 
applied to a 5-cm circular area on the scalp. Two weeks later, a 0.001% DPCP solution is 
applied to the same half of the scalp. The concentration of DPCP is increased gradually each 
week to produce mild inflammation that manifests as pruritus and erythema lasting for 36–48 
h. After establishing the appropriate concentration for the patient, subsequent therapy is con-
tinued once weekly with the same concentration [52]. DPCP should be left on the scalp for 
48 h and the treated area must be protected from the sun during this time. Treatment of both 
sides is recommended only after achieving hair regrowth on the treated side. If there is no 
improvement in 6 months, DPCP is less likely to be successful; however, improvement in 
these "non-responder" patients with longer courses of DPCP therapy has been reported [42, 
53]. If the patient does not develop an allergic reaction to 2% DPCP, SADBE can be tried [42]. 
The procedure with SADBE treatment is similar to DPCP.
The response rates of DPCP treatment in alopecia areata ranges from 5% to 85%. Patients with 
earlier onset of the disease or more extensive involvement were shown to be less likely to 
respond to diphenylcyclopropenone therapy [53].
Topical immunotherapy is generally well tolerated by most of the patients. The most com-
monly seen side effects are eczema, autoeczematization, blistering, and swelling of regional 
lymph nodes [54]. When a vesicular or bullous reaction develops, the patient should wash off 
the contact sensitizer and a topical corticosteroid should be applied to the affected area. Facial 
and scalp edema, contact urticaria, flu-like symptoms, erythema multiforme-like reactions, 
and pigmentary disturbances manifesting as hyperpigmentation, hypopigmentation, dys-
chromia in confetti, and vitiligo can also occur [42, 55, 56]. Patients may complain of burning 
sensation, after application of SADBE. Persistent allergic contact dermatitis of the primary site 
of sensitization, severe generalized dermatitis and systemic reactions characterized by fever, 
and arthalgias are among the rarely observed side effects [54].
10.4. Minoxidil
Topical minoxidil solution, approved by Food and Drug Administration and Health Canada 
for the treatment of androgenetic alopecia, can be used in alopecia areata. Evidence for 
the effectiveness of using 3% minoxidil, twice daily, was shown in a double-blind placebo 
 controlled study [57]. A dose response effect exists, with the 5% solution being more effective 
than the 2% solution. However, few patients achieve cosmetically significant regrowth [58]. 
Minoxidil 5% solution, twice daily, is used in combination with topical or intralesional corti-
costeroids. Contact dermatitis and hypertrichosis are the most common side effects. Minoxidil 
foam, which does not contain propylene glycol, has less irritating effects than the solution [59].
10.5. Anthralin
Anthralin, 0.5–1%, short contact therapy is used as alternative treatment although evidence 
for its efficacy depends on case series without controls [47].
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Anthralin 1% cream is applied daily for 15 or 20 min initially and then washed. The contact time 
is increased by 5 min weekly up to 1 h or to the time required to cause a low-grade dermatitis. 
Once the contact time sufficient to produce the mild dermatitis is found, subsequent therapy is 
continued daily for the established period of time. Anthralin should be applied at least 3 months 
before evaluating the response to treatment. Side effects include severe irritation, folliculitis, 
regional lymphadenopathy, and staining of skin, clothes and fair hair. Patients should avoid eye 
contact with this chemical, and the treated area should be protected from the sun [59].
10.6. Photochemotherapy
No controlled studies of oral or topical psoralen plus ultraviolet A (PUVA) therapy in alopecia 
areata have been reported [59]. The reports about the efficacy of PUVA therapy are conflicting. 
Several studies have shown low response rates of PUVA therapy [60, 61], while others have 
shown good response rates [62, 63]. PUVA therapy is thought to eradicate the mononuclear 
cell infiltrate, surrounding the hair follicle responsible for the disease [16]. Uncertainty about 
efficacy and concerns about PUVA-induced skin carcinogenesis make this therapy option a 
rarely chosen one [59].
10.7. Systemic glucocorticosteroids
Systemic corticosteroids have been used since 1952 in the treatment of alopecia areata; how-
ever, relapse rates are high upon dose reductions [64].
Long-term daily treatment with oral corticosteroids will produce favorable results in a part 
of the patients [33]. It was reported that 12–28% of patients with 1–99% scalp alopecia areata 
regrew 50% or more of their hair after a 6-week tapering course of prednisone therapy, start-
ing at 40 mg daily. 2% minoxidil therapy may be useful for prolonging the response to the 
treatment after prednisone cessation [65]. However, oral corticosteroids are no longer used 
for chronic therapy of alopecia areata because of their side effects [33]. Side effects of oral ste-
roids include avascular necrosis, weight gain, hypertension, diabetes, sleep alteration, mood 
changes, weakness, acneiform eruptions, irregular menses, and striae [52].
High-dose intravenous corticosteroid pulse therapy can be considered in patients with mul-
tifocal or ophiasis-type alopecia areata if treatment with topical sensitizers or highly potent 
topical corticosteroids during 6 months have failed. In more extensive involvement, such as 
alopecia totalis and universalis, treatment efficacy was shown to be diminished [64].
10.8. Immunosuppressive treatment
Immunosuppressive agents namely sulfasalazine, methotrexate, and cyclosporine can be 
used in the treatment of alopecia areata.
Sulfasalazine therapy can be an alternative treatment option in persistent alopecia areata 
cases. Studies have shown favorable treatment response, but a high relapse rate. The most 
common side effects include nausea, vomiting, headache, fever, and rash; less commonly 
hematologic abnormalities and hepatotoxicity can develop [66, 67].
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Severe forms of alopecia areata resistant to conventional topical and/or systemic treatments 
may respond to methotrexate. In a retrospective study, weekly 15–25 mg methotrexate with 
or without 10–20 mg prednisolone daily was reported to be effective in 64% of cases [68].
Cyclosporine has been used alone or in conjunction with corticosteroids variable response rates 
[47]. Use of cyclosporine is limited because of side effects and high relapse rate. Side effects 
include nephrotoxicity, immune suppression, hypertension, and hypertrichosis of body hair [59].
10.9. Other therapies
10.9.1. Excimer laser
Mechanism of action of excimer laser in alopecia areata is thought to depend on induction of 
T cell apoptosis as proven in in vitro studies [69]. In a treatment of 18 patients with 42 alopecia 
areata patches with the 308 nm excimer laser, hair regrowth was observed in 41.5% of treated 
areas. Lesions on the extremities, patients with alopecia totalis, or alopecia universalis were 
resistant to the treatment [70].
10.9.2. Low-dose recombinant interleukin 2
Low-dose interleukin 2 (IL-2) is essential to proliferate Treg cells, which play a key role in 
alopecia areata [71]. A prospective study in 5 patients with extensive, treatment-resistant alo-
pecia areata, 1.5 million IU/d subcutaneous interleukin 2 was administered during 5 days, 
followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9. It was reported that 4 
of the 5 patients attained considerable hair regrowth. Treatment adverse events were mild to 
moderate and included asthenia, arthralgia, urticaria, and injection site reactions [72].
10.9.3. Janus kinase inhibitors
Tofacitinib citrate is a small-molecule selective Janus kinase 1/3 (JAK 1/3) inhibitor that was 
approved by FDA, in late 2012, for the treatment of moderate-to-severe rheumatoid arthritis. 
A patient with longstanding alopecia universalis, treated with tofacitinib for psoriasis had 
hair regrowth, being the first documented case of alopecia areata responding to tofacitinib. 
After eight months of tofacitinib treatment (5 mg twice daily for 2 months followed by 10 mg 
in the morning and 5 mg at night thereafter), the patient had full regrowth of hair at all body 
sites [73]. There have been other case reports showing efficacy of tofacitinib treatment [74, 75]. 
Adverse effects of tofacitinib use include increased risk of severe infections including tuber-
culosis, anemia, neutropenia, headache, and mild nausea [74].
Another JAK inhibitor, ruxolitinib applied topically twice daily for 12 weeks in a patient with 
refractory alopecia universalis induced almost full eyebrow regrowth and approximately 10% 
regrowth of scalp hair [76].
10.9.4. Simvastatin/ezetimibe
Simvastatin 40 mg and ezetimibe 10 mg daily treatment for alopecia totalis and alopecia uni-
versalis was documented to have favorable responses in case reports [77]. In a prospective 
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uncontrolled study, simvastatin/ezetimibe 40 mg/10 mg daily for 24 weeks was shown to be 
an effective treatment option for alopecia areata [78].
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